Stonepine Capital Management’s Edesa Biotech EDSA Stock Holding History

Stonepine Capital Management’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.19M	Buy	456,439 +426,439	+1,421%	+$3.85M	1.8%	20
2026 Q1	$157K	Sell	30,000 -657,500	-96%	-$1.97M	0.06%	74
2025 Q4	$976K	Hold	687,500	–	–	0.71%	39
2025 Q3	$1.7M	Buy	+687,500	New	+$1.59M	1.38%	18
2025 Q2	–	Sell	-687,500	Closed	-$1.68M	–	67
2025 Q1	$1.68M	Buy	+687,500	New	+$1.48M	1.63%	20

Other funds holding EDSA

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Stonepine Capital Management's EDSA Position: Q2 2026 in Review

Stonepine Capital Management increased its Edesa Biotech (EDSA) stake by 1,421% in Q2 2026, buying an estimated $3.85M and bringing the position to 456,439 shares worth $3.19M. The position accounts for 1.8% of the portfolio, ranked #20.

Stonepine Capital Management first reported a position in EDSA in Q1 2025 and has held it in 5 quarters since. 33 funds tracked by Wall St. Rank hold EDSA as of Q2 2026.

Stonepine Capital Management held 456,439 shares of Edesa Biotech worth $3.19M as of Q2 2026.
Stonepine Capital Management bought 426,439 Edesa Biotech shares in Q2 2026, an estimated $3.85M.
Edesa Biotech made up 1.8% of Stonepine Capital Management's portfolio in Q2 2026, its #20 holding.
Stonepine Capital Management first reported a position in Edesa Biotech in Q1 2025 and has held it in 5 quarters since.
33 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.